Page last updated: 2024-12-07

isf 2405

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ISF 2405: metabolite of cadralazine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129853
SCHEMBL ID10844198
MeSH IDM0156907

Synonyms (16)

Synonym
isf 2405
70887-18-2
1-[ethyl-(6-hydrazinylpyridazin-3-yl)amino]propan-2-ol
cadralazine m
isf-2405
cgp 22639
6-(ethyl-(2-hydroxypropyl)amino)-3-hydrazinopyridazine
3(2h)-pyridazinone, 6-(ethyl(2-hydroxypropyl)amino)-, hydrazone
113341-59-6
OWMCFGLDBWRVDZ-UHFFFAOYSA-N
3-[ethyl(2-hydroxypropyl)amino]-6-hydrazinopyridazine
SCHEMBL10844198
1-[ethyl(6-hydrazinylidene-1,6-dihydropyridazin-3-yl)amino]propan-2-ol
DTXSID40921043
1-(ethyl(6-hydrazono-1,6-dihydropyridazin-3-yl)amino)propan-2-ol
STARBLD0008452

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There were no differences between the two groups in AUC and Cmax values of cadralazine and apparent metabolite, the latter defined as the sum of the free and conjugated hydrazinopyridazine."( Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
Brunel, P; Guyene, TT; Imhof, P; Lecaillon, JB; Ménard, J, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's4 (57.14)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.11 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]